Examining the Latest Clinical Findings for Psoriasis and Psoriatic Arthritis to Enhance Managed Care Decision-Making Web Activity

Release date: September 30, 2015
Expiration date: March 30, 2017
Estimated Time to Complete Activity: 1.0 hour
Compatible with all modern web browsers and iOS/Android mobile devices

Distinguished Faculty Presenters


	Neal Birnbaum, MD, FACP, MACR Director, Division of Rheumatology California Pacific Medical Center Clinical Professor of Medicine University of California, San Francisco Click here for biography

	Jeff Dunn, PharmD, MBA Chief Clinical Officer Senior Vice President VRx Pharmacy Services, LLC Click here for biography

	Alan Menter, MD Chief, Division of Dermatology Baylor University Medical Center Chair, Psoriasis Guidelines Committee American Academy of Dermatology Click here for biography

Target Audience

Medical Directors and Pharmacy Directors from health plans, HMOs, integrated health systems, employers, quality organizations, and other managed care organizations (MCOs)
Managed care-affiliated care team members involved with patient evaluation, education, and follow-up for patients with psoriasis and psoriatic arthritis including: physicians, pharmacists, registered nurses, and case managers

Program Overview
As novel agents become available to treat psoriatic disease, treatment decision making is becoming more complex. In light of new drug developments as well as expanding uses of current agents, managed care organizations (MCOs) and payer organizations need to appropriately and effectively design benefits that optimize both cost-efficiency and patient outcomes. This educational activity will include discussions and practical demonstrations of current and emerging clinical data, pharmacy benefit designs, and management resources for managed care professionals to consider.

Educational Objectives
After completing this activity, the participant should be better able to:

Analyze the available evidence-base for the treatment of psoriasis and PsA in a true CER framework
Assess current and emerging therapies for the treatment of psoriasis and PsA and cite their clinical trial data
Address nonadherence factors associated with various therapies for psoriasis and PsA
Integrate interventions to coordinate health plan and affiliated providers efforts in the health care reform era that will lead to better outcomes for patients with psoriasis and PsA
Provide accurate and appropriate counsel as part of the managed care treatment team
Provide appropriate care and counsel for patients and their families

Physician Continuing Medical Education

Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The Annenberg Center for Health Sciences at Eisenhower and Impact Education, LLC. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacist Continuing Education


	Pharmacist Accreditation Statement The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation
This program has been assigned ACPE Universal Activity #0797-9999-15-024-H04-P. This program is designated for up to 1.0 contact hours (0.10 CEUs) of continuing pharmacy education credit.

Type of Activity
Knowledge

Nursing Continuing Education

Nursing Accreditation Statement

Accreditation Statement
Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Credit Designation
A maximum of 1.0 contact hours may be earned for successful completion of this activity.

Disclosure of Conflicts of Interest
The Annenberg Center for Health Sciences at Eisenhower requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to the Annenberg Center for Health Sciences at Eisenhower policy. The Annenberg Center for Health Sciences at Eisenhower is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

*Name of Faculty or Presenter*	*Reported Financial Relationship*
Neal Birnbaum, MD, FACP, MACR	Consulting Fees: Pfizer, Inc. Fees for Non-CME/CE Services Related Directly from a Commercial Interest or their Agents (e.g., speakers’ bureaus): AbbVie, Inc., Amgen, Janssen, Pfizer, Inc.
Jeff Dunn, PharmD, MBA	Consulting Fees: Amgen, Pfizer, Inc.
Alan Menter, MD	Advisory Board: AbbVie, Inc., Allergan, Inc., Amgen, Boehringer Ingelheim Pharmaceuticals,Inc., Eli-Lilly and Company, Genentech, Inc., Janssen Biotech, Inc., LEO Pharma Inc.,Pfizer, Inc. Consulting Fees: AbbVie, Inc., Allergan, Inc., Amgen, Convoy Therapeutics, Inc.,Eli-Lilly and Company, Janssen Biotech, Inc., LEO Pharma Inc.,Novartis Pharmaceuticals Corporation, Pfizer, Inc., Syntrix Biosystems, Inc., Wyeth, XenoPort, Inc. Investigator: AbbVie, Inc., Allergan, Inc., Amgen, Boehringer Ingelheim Pharmaceuticals,Inc., Celgene Corporation, Eli-Lilly and Company, Genentech, Inc., Janssen Biotech, Inc.,LEO Pharma Inc., Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer, Inc.,Symbio/Maruho, Syntrix Biosystems, Inc., Wyeth Speaker: AbbVie, Inc., Amgen, Janssen Biotech, Inc., LEO Pharma Inc., Wyeth Grant: AbbVie, Inc., Allergan, Inc., Amgen, Boehringer Ingelheim Pharmaceuticals, Inc.,Celgene Corporation, Genentech, Inc., Janssen Biotech, Inc., LEO Pharma Inc.,Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer, Inc., Symbio/Maruho,Syntrix Biosystems, Inc. Honoraria: AbbVie, Inc., Allergan, Inc., Amgen, Boehringer Ingelheim Pharmaceuticals, Inc.,Convoy Therapeutics, Inc., Eli-Lilly and Company, Genentech, Inc., Janssen Biotech, Inc.,LEO Pharma Inc., Novartis Pharmaceuticals Corporation, Pfizer, Inc., Syntrix Biosystems, Inc., Wyeth, XenoPort

The planners and managers reported the following financial relationships or relationships to products of devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

*Name of Planner or Manager*	*Reported Financial Relationship*
Steven Casebeer, MBA	No financial interest/relationships relating to the topic of this activity
Sally Schermer, RN, BSN, MBA, CCRN, CPAN, CAPA	Lead Nurse Planner, No financial interest/relationships.
The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
Charles E. Willis, MBA, Director of Continuing Education, Amanda Sewell, MBA, Manager of Continuing Education, Debbie Price, Registration Database Administrator, and Alma Perez, Accreditation Specialist from the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

METHOD OF PARTICIPATION AND REQUEST FOR CREDIT
There are no fees for participating and receiving CME/CE credit for this activity. During the period September 30, 2015 through March 30, 2017, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) successfully complete the post-test with a score of 75% or better; 4) and complete the evaluation form. Upon completion of the full CME/CE activity, your certificate will be made available immediately to download and print.

For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

MEDIA
Internet

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

FEE INFORMATION
There is no fee for this educational activity.